Idenix Drops After Faltering in Patent Dispute: Boston Mover

Idenix Pharmaceuticals Inc., a maker of drugs for viral diseases, fell the most in seven months after losing a decision over whether it or Gilead Sciences Inc. was first to request a patent related to hepatitis C treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.